Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$273.88 USD
-2.45 (-0.89%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ALNY 273.88 -2.45(-0.89%)
Will ALNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
ALNY Down Despite Positive Data From Heart Disease Drug Study
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Other News for ALNY
American Century Focused Dynamic Growth Fund Q2 2024 Commentary
Alnylam Pharma (ALNY) Receives a Buy from Bank of America Securities
TD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Fidelity Select Health Care Portfolio Q2 2024 Review